3.9 Review

The global burden of diabetes and its complications: an emerging pandemic

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1097/01.hjr.0000368191.86614.5a

Keywords

diabetes mellitus type 2; cardiovascular disease; epidemiology; impaired glucose tolerance; impaired fasting glucose; diabetic nephropathy; economic costs

Funding

  1. Netherlands Heart Foundation
  2. Dutch Diabetes Research Foundation
  3. Dutch Kidney Foundation
  4. Pfizer
  5. Roche
  6. Takeda
  7. Johnson and Johnson
  8. Merck Schering Plough
  9. Servier
  10. United Healthcare Group
  11. CTMM, the Center for Translational Molecular Medicine [01C-104]

Ask authors/readers for more resources

The number of patients with type 2 diabetes is increasing rapidly in both developed and developing countries around the world. The emerging pandemic is driven by the combined effects of population ageing, rising levels of obesity and inactivity, and greater longevity among patients with diabetes that is attributable to improved management. The vascular complications of type 2 diabetes account for the majority of the social and economic burden among patients and society more broadly. This review summarizes the burden of type 2 diabetes, impaired glucose tolerance, and their vascular complications. It is projected that by 2025 there will be 380 million people with type 2 diabetes and 418 million people with impaired glucose tolerance. Diabetes is a major global cause of premature mortality that is widely underestimated, because only a minority of persons with diabetes dies from a cause uniquely related to the condition. Approximately one half of patients with type 2 diabetes die prematurely of a cardiovascular cause and approximately 10% die of renal failure. Global excess mortality attributable to diabetes in adults was estimated to be 3.8 million deaths. Eur J Cardiovasc Prev Rehabil 17 (Suppl 1): S3-S8 (C) 2010 The European Society of Cardiology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available